Copy Link Print Information

Capmatinib

(Synonyms: INC280; INCB28060)
26 Cited Publications
Customer Review

Based on 26 publication(s) in Google Scholar

Capmatinib (INC280; INCB28060) is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor (IC50=0.13 nM). Capmatinib can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib is largely metabolized by CYP3A4 and aldehyde oxidase.

For research use only. We do not sell to patients.

  • Purity: 99.71%
  • CAS No.: 1029712-80-8
  • Formula: C23H17FN6O
  • Molecular Weight:412.42
  • Storage:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 2 years , -20°C, 1 year
  • Capmatinib Chemical Structure
    Capmatinib Chemical Structure
  • Experimental Validation Results for Capmatinib
  • Experimental Validation Results for Capmatinib
  • Experimental Validation Results for Capmatinib
  • Experimental Validation Results for Capmatinib
  • Experimental Validation Results for Capmatinib
  • Experimental Validation Results for Capmatinib
CAS No.: 1029712-80-8
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Capmatinib:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Solvent & Solubility
  • Purity & Documentation
  • References
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Capmatinib

More
Customer Validation & Images
In Vivo Efficacy StudyCell Proliferation/Viability AssayWB
  • In Vivo Efficacy Study
  • In Vivo Efficacy Study
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • In Vivo Efficacy Study
  • WB
Keywords
100 mg

Get Quote In-stock

Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Capmatinib Chemical Structure
    Capmatinib Chemical Structure
    1/16
  • 1/16

    Capmatinib purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Jul 17:e00806. [Abstract]

    Customer Validation
     A) Orthotopic inoculated KPC tumors from the control, Capmatinib (INC280) monotherapy, DTA-1 monotherapy and combined therapy groups. B) Quantification of tumor weights under different treatment.Male C57BL/6 mice (KPC cells，orthotopic pancreatic tumor model ), 1) vehicle (5% DMSO + 45% PEG300/5% Tween80 + 50% ddH2O) + IgG control, 2) MET inhibitor monotherapy: INC280 (10 mg kg day−1 for 8 days) + IgG, 3) GITR agonist monotherapy: DTA‐1 (100 µg mouse day−1 for 4 days) + vehicle, and 4) combination therapy: INC280+ DTA‐1. INC280 was formulated in a vehicle solution of DMSO/PEG300/Tween80/ddH₂O (5:45:5:50, v/v) and administered by intraperitoneal injection.

  • 1/16

    Capmatinib purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Jul 17:e00806. [Abstract]

    Customer Validation
     Flowcytometry analysis of GzmB , and TNF-α expression in CD8+ T cells under different treatment. Male C57BL/6 mice (KPC cells，orthotopic pancreatic tumor model ), 1) vehicle (5% DMSO + 45% PEG300/5% Tween80 + 50% ddH2O) + IgG control, 2) MET inhibitor monotherapy: INC280 (Capmatinib, 10 mg kg day−1 for 8 days) + IgG, 3) GITR agonist monotherapy: DTA‐1 (100 µg mouse day−1 for 4 days) + vehicle, and 4) combination therapy: INC280+ DTA‐1. INC280 was formulated in a vehicle solution of DMSO/PEG300/Tween80/ddH2O (5:45:5:50, v/v) and administered by intraperitoneal injection.

  • 1/16

    Capmatinib purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2025 Feb 19;26(4):1766. [Abstract]

    Customer Validation
     In the 3D culture system, MPE primary cells formed stable spheroids within 96 h. Drug sensitivity assays using the 3D tumorsphere model showed that Giotrif (afatinib) at 60 nM and Capmatinib (0.8 nM; 96 h) at 6.5 nM achieved IC50.

  • 1/16

    Capmatinib purchased from MedChemExpress. Usage Cited in: Mol Oncol. 2025 Feb;19(2):474-495. [Abstract]

    Customer Validation
     Capmatinib (0.5,1 μM; 24 h) toxicity was also tested through MTT tests at higher concentration.

  • 1/16

    Capmatinib purchased from MedChemExpress. Usage Cited in: Mol Oncol. 2025 Feb;19(2):474-495. [Abstract]

    Customer Validation
     (A)Graphical representation of tumour volume over time after subcutaneous injection of PC3M Ctrl, PC3M ETV1 and PC3M ERG cells. The tumour volume of the mice was monitored by palpation. (B) Graphical representation of the final tumour volume of mice having been treated or not with Capmatinib.8‐week‐old male NSG‐hHGFki mice (PC3M cells), Capmatinib (10 mg/kg; oral gavage 5 days a week, 30 days).

  • 1/16

    Capmatinib purchased from MedChemExpress. Usage Cited in: Wayne State University. 2014 Jan.

    Customer Validation
     The c-Met Inhibitor INC280 Reveals HGF Activation of c-Met Leads to β4 Activation. (A) Dose-dependent assay to determine the concentration of INC280 required to prevent HGF-induced c-Met phosphorylation. Cells are pre-treated for two hours with INC280 at the indicated concentrations and then stimulated with 50 ng/mL HGF for 30 minutes. Phosphorylated (upper panel) and total c-Met (lower panel) are analyzed by Western blot. Densitometry represents the ratio of phosphorylated to total c-Met as a p

  • Capmatinib